The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

Drug Metabolism and Disposition

Volumn 38, Issue 4, 2010, Pages 667-678

  Blech, Stefan ^a   Ludwig Schwellinger, Eva ^a   Gräfe Mody, Eva Ulrike ^a   Withopf, Barbara ^a   Wagner, Klaus ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7 BUT 2 YN 1 YL 3 METHYL 1 [(4 METHYLQUINAZOLIN 2 YL)METHYL] 8 (3 OXOPIPERIDIN 1 YL) 3,7 DIHYDRO 1H PURINE 2,6 DIONE; 7 BUT 2 YNYL 8 (HYDROXYPIPERIDIN 1 YL) 3 METHYL 1 (4 METHYLQUINAZOLIN 2 YLMETHYL) 3,7 DIHYDROPURINE 2,6 DIONE; 8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; CARBONYL REDUCTASE; CARBOXYLIC ACID DERIVATIVE; CD 10604; CD 1790; CYSTEINE; CYTOCHROME P450 3A4; DEXAMETHASONE; DRUG METABOLITE; FLUFENAMIC ACID; FURAFYLLINE; KETOCONAZOLE; KETONE; LINAGLIPTIN; MEDROXYPROGESTERONE ACETATE; MENADIONE; OXIDOREDUCTASE; PHENOLPHTHALEIN; PIPERIDINE DERIVATIVE; QUERCITRIN; QUINIDINE; RUTOSIDE; SULFAPHENAZOLE; SULFATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACETYLATION; DRUG DISPOSITION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG OXIDATION; DRUG URINE LEVEL; ENANTIOSELECTIVITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIVER MICROSOME METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL; STEREOCHEMISTRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOTRANSFORMATION; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FECES; FEMALE; HEPATOCYTES; HUMANS; INJECTIONS, INTRAVENOUS; ISOTOPE LABELING; MALE; MICROSOMES, LIVER; MIDDLE AGED; PURINES; QUINAZOLINES; SPECTROPHOTOMETRY, ULTRAVIOLET; STEREOISOMERISM; TISSUE DISTRIBUTION;

EID: 77950197593     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.031476     Document Type: Article

References (40)

1. Amet Y, Berthou F, Baird S, Dreano Y, Bail JP, and Menez JF (1995) Validation of the (omega-1)-hydroxylation of lauric acid as an in vitro substrate probe for human liver CYP2E1. Biochem Pharmacol 50:1775-1782.
2. Atalla A, Breyer-Pfaff U, and Maser E (2000) Purification and characterization of oxidoreductases- catalyzing carbonyl reduction of the tobacco-specific nitrosamine 4-methylnitrosamino- 1-(3-pyridyl)-1-butanone (NNK) in human liver cytosol. Xenobiotica 30:755-769.
3. Clarke SE, Baldwin SJ, Bloomer JC, Ayrton AD, Sozio RS, and Chenery RJ (1994) Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. Chem Res Toxicol 7:836-842.
4. Cresteil T, Monsarrat B, Alvinerie P, Tréluyer JM, Vieira I, and Wright M (1994) Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54:386-392.
5. Deyashiki Y, Taniguchi H, Amano T, Nakayama T, Hara A, and Sawada H (1992) Structural and functional comparison of two human liver dihydrodiol dehydrogenases associated with 3 alpha-hydroxysteroid dehydrogenase activity. Biochem J 282:741-746.
6. Drucker DJ (2002) Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531-544.
7. Drucker DJ and Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705.
8. Drucker DJ (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30:1335-1343.
9. Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, Pfrengle W, Guth B, Lotz R, Sieger P, et al. (2007) 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2- ynyl-3-methyl-1-(4-methylquinazonlin- 2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 50:6450-6453.
10. Fuchs H, Binder R, and Greischel A (2009b) Tissue distribution of the novel DPP-4 inhibitor BI1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 30:229-240.
11. Fuchs H, Tillement JP, Urien S, Greischel A, and Roth W (2009a) Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 61:55-62.
12. Gorski JC, Hall SD, Jones DR, Vanden Branden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
13. Graefe-Mody EU, Padula S, Ring A, Withopf B, and Dugi KA (2009) Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin 25:1963-1972.
14. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, and Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
15. Hara A, Taniguchi H, Nakayama T, and Sawada H (1990) Purification and properties of multiple forms of dihydrodiol dehydrogenase from human liver. J Biochem 108:250-254.
16. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, and Dugi KA (2009) Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 11:786-794.
17. Heyn H, White RB, and Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948-954.
18. Holst JJ and Gromada J (2004) Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287:E199-E206.
19. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, and Dugi KA (2008) Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 48:1171-1178.
20. Iffert T, Soldan M, Moeller A, and Maser E (2000) Modulation of daunorubicin toxicity by liposomal encapsulation and use of specific inhibitors in vitro. Toxicology 144:189-195.
21. Kurebayashi H, Tanaka A, and Yamaha T (1982) Oxygen-18 studies on the oxidative deamination mechanism of alicyclic primary amines in rabbit liver microsomes. Arch Biochem Biophys 215:433-443.
22. Kurebayashi H, Tanaka A, Yamaha T, and Tatahashi A (1988) Oxidative deamination of alicyclic primary amines by liver microsomes from rats and rabbits. Xenobiotica 18:1039-1048.
23. Le Cluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon J, Jolley S, and Richert L (2005) Isolation and culture of primary human hepatocytes, in Methods in Molecular Biology, 3rd ed (Helgason CD and Miller CL eds) pp 207-229, Humana Press Inc., Totowa.
24. Ludwig E, Wolfinger H, and Ebner T (1998) Assessment of microsomal tolbutamide hydroxylation by a simple thin-layer chromatography radioactivity assay. J Chromatogr (B) Biomed Appl 707:347-350.
25. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, and Foley JE (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894.
26. Nauck MA, Meier JJ, and Creutzfeldt W (2003) Incretins and their analogues as new antidiabetic drugs. Drug News Perspect 16:413-422.
27. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
28. Nishizawa M, Nakajima T, Yasuda K, Kanzaki H, Sasaguri Y, Watanabe K, and Ito S (2000) Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes to Cells 5:111-125.
29. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug interactions. Drug Metab Dispos 35:246-255.
30. Parli CJ and McMahon RE (1973) The mechanism of microsomal deamination: heavy isotope studies. Drug Metab Dispos 1:337-341.
31. Pelkonen O, Rautio A, Raunio H, and Pasanen M (2000) CYP2A6: a human coumarin 7-hydroxylase. Toxicology 144:139-147.
32. Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, and Fuchs H (2009) Binding to dipeptidylpeptidase-4 determines the disposition of linagliptin (BI1356) - investigations in DPP-4 deficient and wildtype rats. Biopharm Drug Dispos 30:422-436.
33. Rosemond MJ and Walsh JS (2004) Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab Rev. 36:335-361.
34. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
35. Testa B and Caldwell J (2004) The metabolism of drugs and other xenobiotics, biochemistry of redox reactions, in The Metabolism of Drugs and Other Xenobiotics, pp 41-69, Academic Press, London.
36. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, and Mark M (2008a) (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl- quinazolin-2-ylmethyl)- 3,7-dihydro-purine-2,6-dione (BI1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325:175-182.
37. Thomas L, Tadayyon M, and Mark M (2008b) Chronic treatment with the dipeptidyl peptidase-4 inhibitor (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3- methyl-1-(4-methyl-quinazolin-2- ylmethyl)-3,7-dihydro-purine-2,6-dione (BI1356) increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 823:556-563.
38. Wedlund PJ and Wilkinson GR (1996) In vivo and in vitro measurement of CYP2C19 activity. Methods Enzymol 272:105-114.
39. Wild S, Roglic G, Green A, Sicree R, and King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053.
40. Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich FP, and Shimada T (1994) Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol 46:568-577.